Redeye’s comments on Xbrane following its year-end report, which showed negative revenue growth both y/y and q/q. The report also included an unexpected writedown of the milestone payment from Biogen and the upfront payment from Valorum Biologics. We anticipate lowering our fair value range.
LÄS MER
